Patients
| Country | Value | Year |
|---|---|---|
| Iraq | 4.1 | 2023 |
| Jordan | 0.9 | 2023 |
| Lebanon | 1.1 | 2023 |
| Palestine | 1.5 | 2023 |
| Qatar | 2.0 | 2023 |
| Saudi Arabia | 2.2 | 2023 |
| Syria | 1.3 | 2023 |
| UAE | 2.9 | 2023 |
| Yemen | 4.6 | 2023 |
Updated
Reviewed by Chandani Patel
Middle East Bipolar Disorder Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$119.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $217.1 Mn | — | — |
| 2025 (base) | $227.6 Mn | +$10.4 Mn | — |
| 2026 (forecast) | $238.5 Mn | +$10.9 Mn | +4.8% |
| 2027 (forecast) | $249.9 Mn | +$11.4 Mn | +9.8% |
| 2028 (forecast) | $261.9 Mn | +$12.0 Mn | +15.1% |
| 2029 (forecast) | $274.5 Mn | +$12.6 Mn | +20.6% |
| 2030 (forecast) | $287.7 Mn | +$13.2 Mn | +26.4% |
| 2031 (forecast) | $301.5 Mn | +$13.8 Mn | +32.5% |
| 2032 (forecast) | $316.0 Mn | +$14.5 Mn | +38.8% |
| 2033 (forecast) | $331.1 Mn | +$15.2 Mn | +45.5% |
| 2034 (forecast) | $347.0 Mn | +$15.9 Mn | +52.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $227.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $347.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 4.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, type and end user (see all) |
| Key players | AbbVie Inc., Otsuka Pharmaceutical Co., Ltd., Intra-Cellular Therapies, Sumitomo Pharma, GSK PLC (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Bipolar disorder treatment uses mood stabilisers, antipsychotics and therapy to control manic and depressive episodes.
Key segments of the bipolar Disorder Treatment market include drug class (Mood Stabilizers, Antipsychotics and Antidepressants) and type (Bipolar I, Bipolar II and Cyclothymia).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the bipolar Disorder Treatment market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the bipolar Disorder Treatment market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the bipolar Disorder Treatment market.
The bipolar Disorder Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for bipolar Disorder Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.
What doctors and scientists are doing in Bipolar Disorder Treatment right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| Iraq | 4.1 | 2023 |
| Jordan | 0.9 | 2023 |
| Lebanon | 1.1 | 2023 |
| Palestine | 1.5 | 2023 |
| Qatar | 2.0 | 2023 |
| Saudi Arabia | 2.2 | 2023 |
| Syria | 1.3 | 2023 |
| UAE | 2.9 | 2023 |
| Yemen | 4.6 | 2023 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 2 shared keywords
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East
Middle East
OTC & Nutraceuticals · Middle East
Digital Health · Middle East
Digital Health · Middle East
OTC & Nutraceuticals · Middle East
Healthcare Services · Middle East
Public Health · Middle East